41 research outputs found
COVID-19 and nuclear cardiology: Introducing the “forward” virtual visit
[No abstract available
A second wave of COVID-19 infections should not lead to a new disruption of services in nuclear cardiology
[No abstract available
Premature CAD: Conventional Screening and Diagnostic Strategies May Not Capture the “Whole Picture”
[No abstract available
Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA
Molecular imaging and therapy is a rapidly evolving field in research and clinical medicine. The use of the exciting and attractive properties of radioisotopes for imaging and therapy has made Nuclear Medicine very significant when it comes to molecular imaging/therapy. Monoclonal Antibodies (mAbs) on the other hand are very important targeting biomolecules with high affinity that can “carry” the radioisotope of choice. Herein we make a brief overview of the radiolabeled mAbs that target prostate specific membrane antigen (PSMA) and their use in the management of patients with prostate cancer (PCa). © 2018 Taylor & Francis Group, LLC
In the era of FDG PET, is it time for brain perfusion SPECT to gain a place in Alzheimer’s disease imaging biomarkers?
[No abstract available
Detection of extramedullary hematopoietic tissue in a patient with beta-thalassemia major on Tc99m-sestamibi parathyroid scintigraphy
A 50-year-old man with beta-thalassemia major underwent Tc-99m sestamibi parathyroid scintigraphy due to elevated parathyroid hormone and calcium serum levels. Single-photon emission computed tomography imaging of neck and thorax revealed a parathyroid adenoma, as well as increased tracer uptake in a paraspinal region in the right hemithorax, where X-ray and computed tomography of the thorax had shown previously a mass compatible with extramedullary hematopoietic tissue. © 2019 Indian Journal of Nuclear Medicine | Published by Wolters Kluwer - Medknow
Comparison of the magnetic, radiolabeling, hyperthermic and biodistribution properties of hybrid nanoparticles bearing CoFe 2
Metal oxide nanoparticles, hybridized with various polymeric chemicals, represent a novel and
breakthrough application in drug delivery, hyperthermia treatment and imaging techniques.
Radiolabeling of these nanoformulations can result in new and attractive dual-imaging agents
as well as provide accurate in vivo information on their biodistribution profile. In this paper a
comparison study has been made between two of the most promising hybrid core–shell
nanosystems, bearing either magnetite .Fe3O4/ or cobalt ferrite .CoFe2O4/ cores, regarding
their magnetic, radiolabeling, hyperthermic and biodistribution properties. While
hyperthermic properties were found to be affected by the metal-core type, the radiolabeling
ability and the in vivo fate of the nanoformulations seem to depend critically on the size and
the shell composition